March 12, 2020
Annual revision of drug prices would be “practically feasible” because drug makers and pharmacies “still have plenty of financial strength” even after FY2018’s drastic drug pricing reform, and that NHI prices “remain at high levels” even for long-listed products (LLPs),...read more